ALT5 Sigma Sets Record Date for Alyea Therapeutics Separation

ALT5 Sigma Corporation has announced June 2, 2025, as the record date for the anticipated separation of its healthcare arm, Alyea Therapeutics Corporation. This move allows ALT5 to focus separately on its fintech and healthcare segments, with plans for further disposition of its Alyea interests potentially as a split-off or spin-off.

The announcement confirms that equity holders as of the record date will be eligible to participate in the distribution of Alyea. Although no equity holder vote is required at present, ALT5 will keep stakeholders informed if a vote becomes necessary.

Founded in 2018, ALT5 is a fintech company specializing in blockchain technology for digital asset management. Its healthcare division, Alyea, focuses on developing non-addictive pain-relief drugs, with plans to address the opioid crisis.